Capricor Long Term Debt vs Short Long Term Debt Analysis
CAPR Stock | USD 19.64 0.63 3.31% |
Capricor Therapeutics financial indicator trend analysis is way more than just evaluating Capricor Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Capricor Therapeutics is a good investment. Please check the relationship between Capricor Therapeutics Long Term Debt and its Short Long Term Debt accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Capricor Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. To learn how to invest in Capricor Stock, please use our How to Invest in Capricor Therapeutics guide.
Long Term Debt vs Short Long Term Debt
Long Term Debt vs Short Long Term Debt Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Capricor Therapeutics Long Term Debt account and Short Long Term Debt. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Capricor Therapeutics' Long Term Debt and Short Long Term Debt is 0.46. Overlapping area represents the amount of variation of Long Term Debt that can explain the historical movement of Short Long Term Debt in the same time period over historical financial statements of Capricor Therapeutics, assuming nothing else is changed. The correlation between historical values of Capricor Therapeutics' Long Term Debt and Short Long Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Long Term Debt of Capricor Therapeutics are associated (or correlated) with its Short Long Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Short Long Term Debt has no effect on the direction of Long Term Debt i.e., Capricor Therapeutics' Long Term Debt and Short Long Term Debt go up and down completely randomly.
Correlation Coefficient | 0.46 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Long Term Debt
Long-term debt is a debt that Capricor Therapeutics has held for over one year. Long-term debt appears on Capricor Therapeutics balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on Capricor Therapeutics balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.Short Long Term Debt
The total of a company's short-term and long-term borrowings.Most indicators from Capricor Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Capricor Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Capricor Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. To learn how to invest in Capricor Stock, please use our How to Invest in Capricor Therapeutics guide.At this time, Capricor Therapeutics' Selling General Administrative is relatively stable compared to the past year. As of 12/03/2024, Issuance Of Capital Stock is likely to grow to about 9.8 M, while Enterprise Value Over EBITDA is likely to drop (5.41).
Capricor Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Capricor Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Capricor Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 11.1M | 34.6M | 41.3M | 50.1M | 58.7M | 61.7M | |
Total Current Liabilities | 898.0K | 3.0M | 4.1M | 23.6M | 31.3M | 32.8M | |
Total Stockholder Equity | 6.8M | 28.2M | 31.4M | 11.8M | 22.6M | 23.7M | |
Retained Earnings | (74.4M) | (88.0M) | (108.1M) | (137.1M) | (159.4M) | (151.4M) | |
Accounts Payable | 898.0K | 2.7M | 3.7M | 4.8M | 6.2M | 6.5M | |
Non Current Assets Total | 1.2M | 941.7K | 4.9M | 7.2M | 7.9M | 8.3M | |
Non Currrent Assets Other | 779.0K | 88.7K | 275.7K | 268.2K | 308.4K | 234.9K | |
Common Stock Total Equity | 5.2K | 20.6K | 24.2K | 25.2K | 29.0K | 20.1K | |
Common Stock Shares Outstanding | 3.7M | 15.6M | 23.1M | 24.6M | 26.8M | 28.1M | |
Liabilities And Stockholders Equity | 11.1M | 34.6M | 41.3M | 50.1M | 58.7M | 61.7M | |
Other Stockholder Equity | 81.2M | 116.2M | 139.4M | 148.7M | 181.7M | 190.8M | |
Total Liab | 4.3M | 6.4M | 10.0M | 38.3M | 36.1M | 37.9M | |
Common Stock | 5.2K | 20.6K | 24.2K | 25.2K | 31.1K | 20.7K | |
Net Debt | (523.1K) | (32.3M) | (32.0M) | (7.0M) | (12.5M) | (11.8M) | |
Cash | 3.9M | 32.7M | 34.9M | 9.6M | 14.7M | 8.4M | |
Cash And Short Term Investments | 9.9M | 32.7M | 34.9M | 41.4M | 39.5M | 41.5M | |
Net Receivables | 88.0K | 56K | 391.8K | 547.6K | 10.4M | 10.9M | |
Total Current Assets | 9.9M | 33.7M | 36.4M | 42.9M | 50.9M | 53.4M | |
Short Long Term Debt Total | 3.4M | 3.7M | 3.8M | 4.1M | 2.2M | 2.1M | |
Property Plant And Equipment Net | 442.8K | 850.8K | 4.6M | 6.9M | 7.6M | 8.0M | |
Other Current Assets | 571.4K | 1.0M | 1.2M | 919.9K | 995.8K | 572.0K | |
Property Plant And Equipment Gross | 442.8K | 850.8K | 5.4M | 8.1M | 9.8M | 10.3M | |
Accumulated Other Comprehensive Income | 12.4K | (757.0) | 0.0 | 105.2K | 235.8K | 247.6K | |
Intangible Assets | 93.0K | 49.8M | 6.5M | 2.2M | 2.5M | 2.4M | |
Net Tangible Assets | 6.8M | 28.2M | 36.7M | 11.8M | 13.6M | 7.6M | |
Other Assets | 119.6K | 88.7K | 275.7K | 268.2K | 308.4K | 323.8K | |
Retained Earnings Total Equity | (74.4M) | (88.0M) | (108.1M) | (137.1M) | (123.4M) | (117.2M) | |
Short Term Investments | 8.0M | 3.0M | 6.0M | 31.8M | 24.8M | 26.0M | |
Capital Surpluse | 81.2M | 116.2M | 139.4M | 148.7M | 171.0M | 179.6M | |
Inventory | 285.8K | (659.4K) | (56K) | 1.0 | 0.9 | 0.86 | |
Property Plant Equipment | 442.8K | 850.8K | 4.6M | 4.6M | 5.3M | 5.5M |
Pair Trading with Capricor Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Capricor Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Capricor Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Capricor Stock
0.83 | VCNX | Vaccinex | PairCorr |
0.67 | VALN | Valneva SE ADR | PairCorr |
0.67 | DRMA | Dermata Therapeutics | PairCorr |
0.6 | ME | 23Andme Holding | PairCorr |
0.47 | DRRX | Durect | PairCorr |
The ability to find closely correlated positions to Capricor Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Capricor Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Capricor Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Capricor Therapeutics to buy it.
The correlation of Capricor Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Capricor Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Capricor Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Capricor Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Capricor Stock Analysis
When running Capricor Therapeutics' price analysis, check to measure Capricor Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Capricor Therapeutics is operating at the current time. Most of Capricor Therapeutics' value examination focuses on studying past and present price action to predict the probability of Capricor Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Capricor Therapeutics' price. Additionally, you may evaluate how the addition of Capricor Therapeutics to your portfolios can decrease your overall portfolio volatility.